S.V. SHTAIMETS¹, N.G. ZHUKOVA², I.A. ZHUKOVA², A.E. AGASHEVA², D.A. NOVOTNYY³

 ¹Сity Polyclinic No. 3, Omsk

²Siberian State Medical University, Tomsk

³Сity Polyclinic No. 1, Novosibirsk

Contact details:

Shtaimets S.V. — neurologist, Head of Day Care Hospital for Neurological Diseases

Address: 26a Williams St., Omsk, Russian Federation, 644060, tel.: +7-904-321-59-76, e-mail: steinmetz_stas@mail.ru

 The impact of the therapy on patients with Parkinson’s disease remains unclear. To date, claims about the pathogenesis-modifying effect of drugs remain controversial. One of the criteria for the effect of therapy on changing the course of Parkinson’s disease should be an increased life expectancy, a reduction in severe forms and, accordingly, disability. It is only possible to assess the impact of modern therapy by comparing it with a group of patients with Parkinson’s disease who never received modern antiparkinsonian drugs.

The purpose — to study the impact of modern pharmacotherapy on the course of PD based on the data of medical care quality during five years.

Material and methods. A five-year analysis of the conclusions of medical examinations of 1754 patients with Parkinson’s disease, as well as a comparative statistical analysis of the causes of death in the study group compared with the general Russian population in 2018 and a sample of M. Hoehn and M. Yahr 1967, before the use of modern antiparkinsonian drugs.

Results. Out of 1754 people, 1480 patients remained in the study after 5 years. Despite the ongoing drug therapy in accordance with clinical recommendations and standards adopted in the Russian Federation, during the observed period, there was a steady progression of Parkinson’s disease and transition to more severe stages. The mortality rate in the study group from circulatory diseases was significantly higher (p < 0.001) compared to the general Russian population and significantly higher (p < 0.01) compared to the group of M. Hoehn and M. Yahr in 1967, which does not exclude the negative impact of antiparkinsonian drugs. It was interesting to find a reliable fact that in the group of our study, the probability of death from respiratory diseases was 2.23 times higher (p < 0.01) than in the group of Russian citizens in 2018, but 2.38 times lower (p < 0.02) than in the group of M. Hoehn and M. Yahr in 1967, which can be explained by the mutually contradictory effect of antiparkinsonian therapy.

Conclusions. Тhe study established the fact of clinical progression of the disease, despite the ongoing therapy. Over a five-year period, the number of patients in the group with a more severe course of the disease (stages III–IV for Hoehn and Yahr) increased significantly (p < 0.001).

The main causes of death of patients with Parkinson’s disease in our study coincide with the causes of death of Russian citizens in the general population in 2018, as well as with the sample presented by M. Hoehn and M. Yahr in 1967 in the era before the use of modern antiparkinsonian drugs. Modern antiparkinsonian drugs can have both a positive and negative effect on a patient with Parkinson’s disease, having an ambiguous effect on life expectancy.

Key words: Parkinson’s disease, therapy, progression, mortality structure.

REFERENCES

1. Katunina E.A., Bezdol’nyy Yu.N. Epidemiology of Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova, 2013, vol. 113, no. 12, pp. 81–88 (in Russ.).
2. Bharucha N.E., Bharucha E P., Bharucha A.E. et al. Prevalence of Parkinson’s disease in the Parsi community of Bombay, India. Arch. Neurol, 1988, vol. 45 (12), pp. 1321–1323. DOI: 10.1001/archneur.1988.00520360039008
3. Yamawaki M., Kusumi M., Kowa H., Nakashima K. Changes in prevalence and incidence of Parkinson’s disease in Japan during a quarter of a century. Neuro epidemiology, 2009, vol. 32 (4), pp. 263–269. DOI: 10.1159/000201565
4. Wirdefeldt K., Adami H.O., Cole P. et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur. J. Epidemiol, 2011, vol. 26 (1), pp. S1–58. DOI: 0.1007/s10654-011-9581-6
5. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County. Minnesota, 1976 to 1990. Neurology, 1997, vol. 49 (5), p. 284. DOI: 10.1212/wnl.49.5.1284
6. Levin O.S., Fedorova N.V. Bolezn’ Parkinsona [Parkinson’s disease]. Moscow: MEDpress-inform, 2014. 284 p.
7. Abdullah R., Basak I., Patil K.S. et al. Parkinson’s disease and age: The obvious but largely unexplored link. Exp. Gerontol, 2015, vol. 68, pp. 33–38. DOI: 10.1016/j.exger.2014.09.014
8. Raspredelenie naseleniya po vozrastnym gruppam [Distribution of the population by age groups], available at: https://gks.ru/folder/12781___doc/demo14(1).xls (accessed on: 19.02.2020)
9. Levin O.S. How was Parkinson’s disease treated in 2013. Sovremennaya terapiya v psikhiatrii i nevrologii, 2013, no. 3–4, pp. 5–16 (in Russ.).
10. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. 1967. Neurology, 2001, vol. 17, no. 10, suppl. 3, pp. S11–26.
11. Hely M.A., Morris L.G., Traficante R. et al. The Sydney multicenter study of Parkinson’s disease: progression and mortality at 10 years. J. Neurol. Neurosurg. Psychiatry, 1999, vol. 67 (3), pp. 300–307. DOI: 10.1136/jnnp.67.3.300
12. Forsaa E.D., Larsen J.P., Wentzel-Larsen T., Alves G. What predicts mortality in Parkinson disease? A prospective population-based long-term study. Neurology, 2010, vol. 75 (14), pp. 1270–1276. DOI: 10.1212/WNL.0b013e3181f61311
13. Goldstein D.S., Holmes C., Sharabi Y., Wu T. Survival in synucleinopathies: A prospective cohort study. Neurology, 2015, vol. 85 (18), pp. 1554–1561. DOI: 10.1212/WNL.0000000000002086
14. Schapira A.H., McDermott M.P., Barone P. et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomized delayed-start trial. Lancet Neurol, 2013, vol. 12 (8), pp. 747–755. DOI: 10.1016%2FS1474-4422(13)70117-0
15. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol., 2004, vol. 61 (4), pp. 561–566. DOI: https://doi.org/10.1001/archneur.61.4.561
16. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch. Neurol., 2002, vol. 59 (12), pp. 1937–1943. DOI: 10.1001/archneur.59.12.1937
17. Hauser R.A., Lew M.F., Hurtig H.I. et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Movement Disord, 2009, vol. 24 (4), pp. 564–573. DOI: 10.1002/mds.22402
18. Olanow C.W., Hauser R.A., Jankovic J. et al. A randomized, double-blind, placebocontrolled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (The ADAGIO Study): rationale, design, and baseline characteristics. Movement Disord, 2008, vol. 23 (15), pp. 2194–2201. DOI: 10.1002/mds.22218
19. Olanow C.W., Rascol O., Hauser R. et al. A doubled-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med, 2009, vol. 361 (13), pp. 1268–1278. DOI: 10.1056/NEJMoa0809335
20. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson‘s disease. N. Engl. J. Med, 1993, vol. 328 (3), pp. 176–183.
21. The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson‘s disease. Ann Neurol, 1996, vol. 40 (1), pp. 99–107. DOI: https://doi.org/10.1002/ana.410400116
22. Natsional’noe obshchestvo po izucheniyu bolezni Parkinsona i rasstroystv dvizheniy, Soyuz reabilitologov Rossii. Reabilitatsiya pri bolezni Parkinsona i sindrome parkinsonizma pri drugikh zabolevaniyakh. Klinicheskie rekomendatsii [National Society for the Study of Parkinson’s Disease and Movement Disorders, Union of Rehabilitologists of Russia. Rehabilitation in Parkinson’s disease and parkinson’s syndrome in other diseases. Clinical guidelines], 2018, available at: https://rehabrus.ru/Docs/2019/rekomendacii-po-reabilitacii-parkinsonizma-smolenceva.pdf (accessed on: 21.03.2020).
23. Svedeniya o smertnosti naseleniya po prichinam smerti po RF za yanvar’ — dekabr’ 2018 g. (operativnye dannye bez ucheta okonchatel’nykh meditsinskikh svidetel’stv o smerti) [Data on the mortality of the population by causes of death in the Russian Federation for January — December 2018 (operational data without taking into account the final medical certificates of death)], available at: https://www.gks.ru/free_doc/2018/demo/t3_3.xls